Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of CKD-396 vs Co-administration of CKD-501 and D759
NCT04246190Phase 1Unknown
- Sponsor
- Chong Kun Dang Holdings
- Start
- Feb 2020
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Duvie S in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve to the Last Measurable Concentration. Status: unknown.
02
Drugs
Duvie S
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04246190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04246190.